TG Therapeutics, Inc. (TGTX)
TGTX Stock Price Chart
Explore TG Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TGTX price movements and trends.
TGTX Company Profile
Discover essential business fundamentals and corporate details for TG Therapeutics, Inc. (TGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 May 2010
Employees
352.00
Website
https://www.tgtherapeutics.comCEO
Michael S. Weiss
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Financial Timeline
Browse a chronological timeline of TG Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.25, while revenue estimate is $152.95M.
Earnings released on 4 Aug 2025
EPS came in at $0.17 falling short of the estimated $0.32 by -46.88%, while revenue for the quarter reached $141.15M , missing expectations by -3.50%.
Earnings released on 5 May 2025
EPS came in at $0.03 falling short of the estimated $0.18 by -83.33%, while revenue for the quarter reached $120.86M , missing expectations by -9.94%.
Earnings released on 3 Mar 2025
EPS came in at $0.15 surpassing the estimated $0.08 by +87.50%, while revenue for the quarter reached $108.19M , missing expectations by -0.57%.
Earnings released on 4 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.03 by -33.33%, while revenue for the quarter reached $83.88M , missing expectations by -15.09%.
Earnings released on 6 Aug 2024
EPS came in at $0.04 surpassing the estimated -$0.05 by +180.00%, while revenue for the quarter reached $73.47M , beating expectations by +11.50%.
Earnings released on 1 May 2024
EPS came in at -$0.07 falling short of the estimated -$0.04 by -96.02%, while revenue for the quarter reached $63.47M , beating expectations by +16.23%.
Earnings released on 28 Feb 2024
EPS came in at -$0.09 surpassing the estimated -$0.12 by +25.00%, while revenue for the quarter reached $43.97M , beating expectations by +9.76%.
Earnings released on 1 Nov 2023
EPS came in at $0.73 surpassing the estimated $0.12 by +508.33%, while revenue for the quarter reached $165.82M , beating expectations by +328.68%.
Earnings released on 1 Aug 2023
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $16.07M , missing expectations by -65.90%.
Earnings released on 1 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.36 by +22.22%, while revenue for the quarter reached $7.80M , missing expectations by -45.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.39 falling short of the estimated -$0.26 by -50.00%, while revenue for the quarter reached $80.00K , missing expectations by -95.01%.
Earnings released on 10 Nov 2022
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%, while revenue for the quarter reached $94.00K , missing expectations by -93.54%.
Earnings released on 8 Aug 2022
EPS came in at -$0.30 surpassing the estimated -$0.49 by +38.78%, while revenue for the quarter reached $594.00K , beating expectations by +238.60%.
Earnings released on 10 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.55 by +7.27%, while revenue for the quarter reached $2.02M , missing expectations by -3.11%.
Earnings released on 1 Mar 2022
EPS came in at -$0.70 falling short of the estimated -$0.62 by -12.90%, while revenue for the quarter reached $2.32M , beating expectations by +3.62%.
Earnings released on 4 Nov 2021
EPS came in at -$0.65 falling short of the estimated -$0.56 by -16.07%, while revenue for the quarter reached $2.03M , missing expectations by -31.65%.
Earnings released on 2 Aug 2021
EPS came in at -$0.59 falling short of the estimated -$0.48 by -22.92%, while revenue for the quarter reached $1.55M , missing expectations by -55.73%.
Earnings released on 10 May 2021
EPS came in at -$0.69 falling short of the estimated -$0.52 by -32.69%, while revenue for the quarter reached $793.00K , beating expectations by +2.99%.
Earnings released on 2 Mar 2021
EPS came in at -$0.71 falling short of the estimated -$0.57 by -24.56%, while revenue for the quarter reached $38.00K .
Earnings released on 9 Nov 2020
EPS came in at -$0.73 falling short of the estimated -$0.41 by -78.05%, while revenue for the quarter reached $38.00K , beating expectations by +22.72%.
TGTX Stock Performance
Access detailed TGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.